Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis
Anoop N Koshy, Alexandra C Murphy, Omar Farouque, Jay Ramchand, Louise M Burrell, Matias B Yudi
Internal Medicine Journal | WILEY | Published : 2020
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, enters human cells by binding of its viral protein to the aminopeptidase angiotensin-converting enzyme 2 (ACE2). This has led to speculation whether treatment with renin-angiotensin system (RAS) inhibitors was associated with an increased likelihood of a positive test for COVID-19 and risk of mortality. AIMS: We performed a systematic review and meta-analysis to investigate whether RAS inhibitors increased the likelihood of a positive test or death/severe illness in patients with COVID-19. METHODS: A systematic search of MEDLINE, PubMed and EMBASE was conducted for studies stratified by..View full abstract
Awarded by Royal Australasian College of Physicians Blackburn Scholarship
A. N. Koshy is a recipient of the National Health and Medical Research Council of Australia/National Heart Foundation Post-Graduate Scholarship and Royal Australasian College of Physicians Blackburn Scholarship (1150874). A. C. Murphy is supported by the Cardiac Society of Australia and New Zealand PhD Scholarship.